A recent prospective study has demonstrated that overweight and obese patients had a better Disease Activity in Psoriatic Arthritis (DAPSA) score compared with their normo-weight counterparts (78), and serum IL-17 seem to correlate BMI, pointing to an association between obesity and IL-17 and thus, a potential better clinical benefit in patients with obesity. This evidence concerns the gene IL17A and psoriatic arthritis.